PURPOSE: To evaluate the feasibility and efficacy of a sequential administration of four cycles of @entity1205 (100 mg/m(2) every 3 weeks) followed by four cycles of @entity632 and @entity786 (AC; 60/600 mg/m(2) every 3 weeks), with subsequent consolidation with @entity1205 or AC, as first-line chemotherapy in @entity1 with @entity0 ( @entity0 ). @entity1 AND METHODS: Forty-eight @entity1 received 443 cycles of chemotherapy (median, 11 cycles/ @entity1 ; range, 1 to 13 cycles). A total of 267 cycles of @entity1205 (60.3%) and 176 of AC (39.7%) were given. Consolidation therapy was given to 33 @entity1 (29 with @entity1205 ). RESULTS: Grade 4 @entity1398 was the most frequent @entity137 (83% of @entity1 ). This was not cumulative and was rarely complicated by @entity1398 or severe @entity281 . The nonhematologic safety profile was favorable: there were no grade 4 adverse events, and grade 3 episodes were infrequent. @entity1205 -specific @entity137 were generally not severe. With a median cumulative @entity632 dose of 397 mg/m(2) (range, 150 to 543 mg/m(2)), two incidences of unrelated congestive @entity712 after further treatment with @entity8253 and two of asymptomatic left ventricular ejection fraction decrease were observed. Among the 42 assessable @entity1 , five (12%) had complete and 25 (60%) had partial responses, for an overall response rate of 71% (95% confidence interval, 55% to 84%). Median duration of response was 53 weeks (range, 12 to 72 weeks), and median time to progression was 46 weeks (range, 3 of 72 weeks). With a median follow-up of 40.4 months, median survival was 32 months (range, 2 to 55 months). CONCLUSION: This @entity1205 -based sequential schedule is safe and effective in first-line therapy for @entity0 , without incurring cumulative @entity137 , and provides a feasible chemotherapeutic option in this clinical setting.

Phase II study of sequential administration of @entity1205 followed by @entity632 and XXXX as first-line chemotherapy in @entity0 .

@entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure'] @entity0 :: ('MESH:D001943', 'Disease') :: ['metastatic breast cancer', 'MBC'] @entity8253 :: ('MESH:D018943', 'Chemical') :: ['anthracyclines'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel', 'Docetaxel']
@entity786 :: (MESH:D003520,Chemical) :: ['cyclophosphamide']
